Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Initiative focused on driving gross profit margin and path to profitability for the ALL business Company will reduce headcount by approximately 13% while doubling manufacturing of products for commercial and clinical trial patients in 2026 Autolus reiterates full year 2026 AUCATZYL® net product revenue of $120 million to $135 million, up from $74 million in 2025, as well as an anticipated shift to positive gross margin in 2026 Clinical development programs are on track and include CATULUS, a pivotal Phase 2 trial in pediatric relapsed/refractory acute lymphoblastic leukemia; LUMINA, a pivotal Phase 2 trial in lupus nephritis; and BOBCAT, an exploratory Phase 1 trial in progressive multiple sclerosis LONDON and GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced a strategic initiative and plan to improve operational efficiency and reduce operating expenses.

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 68,500 American Depositary Shares and 57,765 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 15 employees pursuant to the Company's 2025 Inducement Plan.

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025 AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluation Autolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026 Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Pivotal Phase 2 clinical trials with obe-cel in ​lupus nephritis and pediatric ALL enrolling; initial clinical data from BOBCAT Phase 1 trial in progressive MS anticipated by year-end 2026 Conference call to be held today at 08:30 am EDT/12:30 pm GMT: conference call participants should pre-register using the link at the bottom of this press release LONDON and GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces its operational and financial results for the fourth quarter and full year ended December 31, 2025.

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares, to 22 employees pursuant to the Company's 2025 Inducement Plan.